Baidu
map

重磅:2016年ESMO全新发布指南 TOP10

2016-12-22 MedSci MedSci原创

2016年欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology)发布了一系列肿瘤指南,梅斯医学小编对这些指南进行了整理,与大家分享。 1.2016 ESMO共识指南:转移性结直肠癌患者的管理2016年7月,欧洲肿瘤内科学会(ESMO)发布了转移性结直肠癌患者的管理指南,结直肠癌是西方国家常见的恶性肿瘤之一,在过去的20年里,特别是过去的1

2016年欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology)发布了一系列肿瘤指南,梅斯医学编辑对这些指南进行了整理,与大家分享。 

1.2016 ESMO共识指南:转移性结直肠癌患者的管理

2016年7月,欧洲肿瘤内科学会(ESMO)发布了转移性结直肠癌患者的管理指南,结直肠癌是西方国家常见的恶性肿瘤之一,在过去的20年里,特别是过去的10年中,转移性结直肠癌患者的临床结局已经得到了极大地改善。该指南主要基于当前证据为转移性结直肠癌患者的管理和治疗提供了循证建议。 

2.2016 ESMO临床实践指南:成人急性淋巴细胞性白血病的诊断,治疗和随访

2016年4月,欧洲肿瘤内科学会(ESMO)发布了成人急性淋巴细胞性白血病(ALL)的诊断,治疗和随访指南,指南这涉及的主要内容包括:发病率和流行病学;诊断、病理/分子生物学;风险评估和预后因素;新诊断ALL的治疗;难治性和复发性ALL的治疗;随访和长期影响等内容。 

3.2016 ESMO临床实践指南:结外弥漫性大B细胞淋巴瘤(DLBCL)和原发性纵隔B细胞淋巴瘤的诊断,治疗和随访

2016年7月,欧洲肿瘤内科学会(ESMO)发布了结外弥漫性大B细胞淋巴瘤(DLBCL)和原发性纵隔B细胞淋巴瘤的诊断,治疗和随访指南,目的是针对淋巴结外侵犯的弥漫性大B细胞淋巴瘤提出实践指南和建议,主要内容涉及发病率和流行病学,分子/病理学诊断,分期和风险评估,治疗,随访以及个体化医疗等。 

4.2016 ESMO临床实践指南:肾细胞癌的诊断,治疗及随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了肾细胞癌的诊断,治疗及随访指南,指南主要内容涉及肾细胞癌的发病率和流行病学,诊断,病理学评估,分期和风险评估,不同类型疾病的管理,治疗反应评估,随访监测等内容。 

5.2016 ESMO临床实践指南:食管癌的诊断,治疗及随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了最新食管癌诊断、治疗以及随访指南,指南主要内容涉及食管癌的发病率和流行病学,诊断以及病理/分子生物学,分期和风险评估,各种疾病类型的管理,个体化医疗,随访和长期影响等。 

6.2016 ESMO临床实践指南:转移性非小细胞肺癌的诊断、治疗和随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了转移性非小细胞肺癌的诊断、治疗和随访指南,指南主要内容包括:发病率和流行病学,诊断和个体化医疗,分期和风险评估,各期疾病的治疗,疗效评估和随访等。 

7.2016 ESMO临床诊疗指南:BRCA突变携带者以及其他乳腺/卵巢遗传性癌症综合征的预防和筛查

2016年9月,欧洲肿瘤内科学会(ESMO)发布了BRCA突变携带者以及其他乳腺/卵巢遗传性癌症综合征的预防和筛查指南,指南主要聚焦携带基因BRCA1/2突变个体的癌症筛查和预防。指南主要内容包括发病率和流行病学,BRCA基因突变的咨询和随访,乳腺癌卵巢癌风险的降低,BRCA基因突变的筛查等。 

8.2016 ESMO临床诊疗指南:胆管癌的诊断、治疗与随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了胆管癌的诊断、治疗与随访指南,指南主要内容包括:发病率和流行病学,诊断以及病理/生物分子,分期和风险评估,各种类型疾病的治疗,个体化医疗,监测和随访等。 

9.2016 ESMO临床诊疗指南:胃癌的诊断、治疗与随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了胃癌的诊断、治疗与随访指南,指南主要内容包括:发病率和流行病学,诊断以及病理,分期和风险评估,治疗计划,各种类型疾病的治疗,个体化医疗和靶向治疗,监测和随访等。 

10.2016 ESMO临床诊疗指南:新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

2016年9月,欧洲肿瘤内科学会(ESMO)发布了新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访指南,指南主要内容涉及滤泡性淋巴瘤的发病率和流行病学,诊断以及分子诊断,分期和风险评估,治疗,个体化医疗,随访监测等内容。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-04-16 liuhuangbo
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2017-01-21 respect
  4. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-24 hb2008ye
  5. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-24 xxxx1054
  6. [GetPortalCommentsPageByObjectIdResponse(id=2024789, encodeId=97702024e898f, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun Apr 16 05:08:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814752, encodeId=c3161814e52f1, content=<a href='/topic/show?id=bd3d960016d' target=_blank style='color:#2F92EE;'>#重磅:2016年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96001, encryptionId=bd3d960016d, topicName=重磅:2016年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Aug 08 04:08:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649814, encodeId=bec51649814be, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Jan 21 11:08:00 CST 2017, time=2017-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280936, encodeId=f02c1280936fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548975, encodeId=fd3515489e538, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Dec 24 03:08:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164872, encodeId=56031648e274, content=很好,不错的资料,值得收藏,给自己学习探究提供了方便。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Dec 22 13:24:31 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-22 虈亣靌

    很好,不错的资料,值得收藏,给自己学习探究提供了方便。

    0

相关资讯

详解2016年FDA批准的20款创新药(名称、活性成分、适应症……)

导读 12月14日,FDA公布了2016年批准的第20个新分子药物Eucrisa,而后朋友圈被“CDER新药办公室主任John K. Jenkins博士的FDA新药审评情况”一文刷屏了。到目前为止FDA仅批准20个新分子药物,远低于去年的45个。本文详细解析了这20款创新药物的名称、活性成分、适应症……截止至2016年12月14日,FDA下属药品审评与研究中心(CDER)共批准了20个创新药:包括

重磅:2016年AHA全新发布指南 TOP15

2016年美国心脏协会(AHA,American Heart Association)发布了一系列心血管病指南,梅斯医学小编对这些指南进行了整理,与大家分享。 1. 2016 ACC/AHA/HFSA临床指南:新药物治疗心力衰竭2016年5月,美国心脏病学会(ACC)、美国心脏协会(AHA)以及美国心衰学会(HFSA)共同更新发布了新药物治疗心力衰竭指南,该指南是对2013

重磅:2016年NCCN全新发布指南 TOP30

2016年美国国家综合癌症网络(NCCN)发布了一系列指南,梅斯医学小编针对常见肿瘤和多发肿瘤对NCCN在2016年最新发布的指南进行了整理,与大家分享。 1 2017 NCCN临床实践指南:子宫肿瘤(2017.V1)2016年11月,美国国家综合癌症网络(NCCN)发布了子宫肿瘤指南2017年第1版。 2 2017 NCCN临床实践指南:直肠癌(2017.V1)2016年

盘点:2016年人工智能在医疗领域的发展

2016年,“人工智能”一词火了起来,啥是人工智能?人工智能是研究、开发用于模拟、延伸和扩展人的智能的理论、方法、技术及应用系统的一门新的技术科学;它是计算机科学的一个分支,企图了解智能的实质,并生产出一种新的能以人类智能相似的方式做出反应的智能机器,该领域的研究包括机器人、语言识别、图像识别、自然语言处理和专家系统等。1946年,第一台电子计算机ENIAC在美国诞生(另一说法是阿塔纳索夫•贝瑞计

2016年中国医疗电子市场产值将达74亿美元

相关研究机构预测,截至2016年,中国医疗电子市场产值将达到74亿美元,平均年复合率为13%。主要也是因为,全球对断层扫描仪、磁共振仪、高档超声波诊断仪器等产品的需求快速增长,带动了全球医疗电子市场规模的扩大。作为全球领先的高性能信号处理解决方案供应商,ADI公司一直致力于医疗电子产品开发与技术创新,并将继续保持其在医疗电子领域的优势,持续增加投入力度。ADI公司亚太区医疗行业市场经理王胜接受采访

Baidu
map
Baidu
map
Baidu
map